



PRESS RELEASE

Half-year report on the liquidity contract

Eragny-sur-Oise (France), January 11, 2016 – SAFE ORTHOPAEDICS (Euronext: FR0012452746 – SAFOR), a company developing and marketing an innovative range of sterile implants combined with their single-use surgical instruments, releases its six-monthly report on the liquidity contract signed with Invest Securities.

The liquidity account had the following holdings as of December 31, 2015:

- 29,384 shares
- €47,132.52

For the prior (June 30, 2015), the corresponding figures were:

- 16,306 shares
- €76,485

About Safe Orthopaedics

Founded in 2010, Safe Orthopaedics is a French medical technology company that develops and markets an innovative range of sterile implants and associated single-use surgical instruments, with the aim of facilitating safer, optimized and lower-cost spinal surgery. By avoiding the reuse of surgical instruments, Safe Orthopaedics reduces the risk of infection, avoids the cumbersome and unreliable logistics of instrument sterilization, and limits hospital costs. Protected by 17 patent families, the SteriSpine™ Kits are CE-marked and FDA cleared; they are already being marketed in 16 countries, in Europe and the United States. They are being rapidly adopted by surgeons throughout the world, with nearly 1,000 procedures performed in 2014 and 1,691 from January 1st until September 30th 2015. The company is based at Eragny-sur-Oise (France), and has 32 employees and a US subsidiary.

For more information, visit: www.SafeOrtho.com

Contacts

Safe Orthopaedics

Yves Vignancour
CEO

Thierry Lambert
CFO

Tel.: +33 (0)1 34 21 50 00

investors@safeorthopaedics.com

NewCap

Julien Perez / Valentine Brouchet
Investor Relations

Nicolas Merigeau
Media Relations

Tel.: +33 (0)1 44 71 94 94

SafeOrtho@newcap.eu

SAFOR
LISTED
EURONEXT